Universität zu Köln

Sprenger, Tobias, Schirrmacher, Volker, Stuecker, Wilfried and van Gool, Stefaan W. (2020). Position paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies. Expert Rev. Anticancer Ther, 20 (8). S. 639 - 647. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1744-8328

Full text not available from this repository.

Abstract

Introduction Prospective double-blind placebo-controlled randomized clinical trials (RCTs) are considered standard for the proof of the efficacy of oncologic therapies. Molecular methods have provided new insights into tumor biology and led to the development of targeted therapies. Due to the increasing complexity of molecular tumor characteristics and of the individuality of specific anti-tumor immune reactivity, RCTs are unfortunately only of limited use. Areas covered The historical methods of drug research and approval and the related practices of reimbursement by statutory and private health insurance companies are being questioned. New, innovative methods for the documentation of evidence in personalized medicine will be addressed. Possible perspectives and new approaches are discussed, in particular with regard to glioblastoma. Expert opinion Highly specialized translational oncology groups like the IOZK can contribute to medical progress and quick transfer 'from bench to bedside.' Their contribution should be acknowledged and taken into account more strongly in the development of guidelines and the reimbursement of therapy costs. Methodological plurality should be encouraged.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Sprenger, Tobias UNSPECIFIED UNSPECIFIED UNSPECIFIED Schirrmacher, Volker UNSPECIFIED UNSPECIFIED UNSPECIFIED Stuecker, Wilfried UNSPECIFIED UNSPECIFIED UNSPECIFIED van Gool, Stefaan W. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-328992
DOI:	10.1080/14737140.2020.1785874
Journal or Publication Title:	Expert Rev. Anticancer Ther
Volume:	20
Number:	8
Page Range:	S. 639 - 647
Date:	2020
Publisher:	TAYLOR & FRANCIS LTD
Place of Publication:	ABINGDON
ISSN:	1744-8328
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ADJUVANT TEMOZOLOMIDE; RESISTANCE MECHANISMS; PERSONALIZED MEDICINE; SUCCESS RATES; CANCER; GLIOBLASTOMA; RADIOTHERAPY; THERAPY; METAANALYSIS; BENEFIT Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/32899